Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States

Transplantation

Volumn 99, Issue 6, 2015, Pages 1165-1171

  Schold, Jesse ^a   Poggio, Emilio ^a   Goldfarb, David ^a   Kayler, Liise ^b   Flechner, Stuart ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; CREATININE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BK VIRUS; CAUSE OF DEATH; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; SELECTION BIAS; UNITED STATES; ACUTE DISEASE; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; GRAFT REJECTION; GRAFT SURVIVAL; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; PROCEDURES; REOPERATION; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; CREATININE; DELAYED GRAFT FUNCTION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; REOPERATION; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84930536335     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000507     Document Type: Article

References (36)

1. Organ Procurement and Transplantation Network. Transplants by Donor Type. http://optn. Transplant. hrsa. gov/latestData/rptData. asp. 5-17-2013. Ref Type: Electronic Citation.
2. Miles CD, Schaubel DE, Jia X, et al. Mortality experience in recipients undergoing repeat transplantation with expanded criteria donor and non-ECD deceased-donor kidneys. Am J Transplant 2007;7:1140.
3. Rao PS, Schaubel DE, Wei G, et al. Evaluating the survival benefit of kidney retransplantation. Transplantation 2006;82:669.
4. Gralla J, Tong S, Wiseman AC. The impact of human leukocyte antigen mismatching on sensitization rates and subsequent retransplantation after first graft failure in pediatric renal transplant recipients. Transplantation 2013;95:1218.
5. Meier-Kriesche HU, Scornik JC, Susskind B, et al. A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients Transplantation 2009;88:23.
6. Heaphy EL, Poggio ED, Flechner SM, et al. Risk factors for retransplant kidney recipients: relisting and outcomes from patients' primary transplant. Am J Transplant 2014;14:1356.
7. Schold JD, Buccini LD, Goldfarb DA, et al. Patient participation in research among solid organ transplant recipients in the United States. Transplantation 2011;91:1424.
8. Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. In: Transpl Int 2013;26:662.
9. Mourad G, Garrigue V, Squifflet JP, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation 2001;72:1050.
10. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl JMed 2006;355:1967.
11. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011;364:1909.
12. Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-Analysis of randomized trials. Transplantation 2004;77:166.
13. Webster AC, Ruster LP, McGee R, et al. Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010: CD003897.
14. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003;76:1289.
15. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant 2007;7:2619.
16. Kuo HT, Huang E, Emami S, et al. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients. Transplantation 2012;93:493.
17. Gill J, Sampaio M, Gill JS, et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol 2011;6:1168.
18. Hussain SM, Sureshkumar KK, Ko TY, et al. Effect of induction agent on posttransplant outcomes in deceased donor kidney transplant recipients: influence of race. Transplant Proc 2013;45:119.
19. Jindal RM, Das NP, Neff RT, et al. Outcomes in African-Americans vs. Caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: Analysis of USRDS database. Am J Nephrol 2009;29:501.
20. Sureshkumar KK, Hussain SM, Zimmer BW, et al. Emerging role of Alemtuzumab in renal and renal-pancreas transplantation. Expert Opin Biol Ther 2008;8:1605.
21. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4:87.
22. Gaber AO, Matas AJ, Henry ML, et al. Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation 2012;94:331.
23. Zhang X, Huang H, Han S, et al. Alemtuzumab induction in renal transplantation: A meta-Analysis and systemic review. Transpl Immunol 2012;27:63.
24. Emami S, Huang E, Kuo HT, et al. Multivariate analysis of antibody induction therapy and their associated outcomes in live donor kidney transplantation in the recent era. Clin Transplant 2012;26:351.
25. Fleming JN, Taber DJ, Weimert NA, et al. Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients. Transpl Int 2010;23:500.
26. Ison MG, Parker M, Stosor V, et al. Development of BK nephropathy in recipients of simultaneous pancreas-kidney transplantation. Transplantation 2009;87:525.
27. Lipshutz GS, Flechner SM, Govani MV, et al. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004;4:2132.
28. Manitpisitkul W, Drachenberg C, Ramos E, et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: A casecontrol study. Transplantation 2009;88:83.
29. Schold JD, Rehman S, Kayle LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009;22:626.
30. Theodoropoulos N, Wang E, Penugonda S, et al. BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation. Am J Transplant 2013;13:197.
31. Schold JD, Kaplan B. The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am J Transplant 2010;10:1163.
32. Ibrahim A, Garg AX, Knoll GA, et al. Kidney function endpoints in kidney transplant trials: A struggle for power. Am J Transplant 2013;13:707.
33. Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making 2009;29:661.
34. Austin PC. The performance of different propensity-score methods for estimating differences in proportions(risk differences or absolute risk reductions) in observational studies. Stat Med 2010;29:2137.
35. Akkina SK, Connaire JJ, Israni AK, et al. Similar outcomes with different rates of delayed graft function may reflect center practice, not center performance. Am J Transplant 2009;9:1460.
36. Levine GN, McCullough KP, Rodgers AM, et al. Analytical methods and database design: implications for transplant researchers, 2005. Am J Transplant 2006;6:1228.